Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.08 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: masoprocol, veligrotug, conteltinib +17 | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 25 Parkinson's papers of 6,979 | 0.57 |
| pathways Reactome | 5 pathways; mostly growth signalling | 0.60 |
No case: the score is under the bar. Receipt 3205
Sealed predictions
- IGF1R in dopamine neurons, braak-0.21 (p 0.583) → -0.53 (p 0.138)receipt 3212
Swarm cases
receipt 3212: IGF1R in dopamine neurons, braak
- power
- full sample -0.40 (p 0.103, n 18), 95% CI -0.73 to +0.09. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.39 (p 0.114, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.46 (p 0.052, n 18). could be the mix.
- skeptic
- leave-one-out range -0.56 to -0.32, sign flips 0; without severely affected donors -0.40 (p 0.103, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for IGF1R in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts